BioSpace News Archive

IQ4I Research & Consultancy published a new report on “Proteomics Global Market – Forecast To 2026".

New Thermo Scientific Vanquish Core HPLC System maximizes the delivery of precise results with simple, seamless method transfer

Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA) and the nation’s leading network of dialysis facilities, has launched an online community to connect people impacted by kidney disease

Cyclo Therapeutics Announces Positive Feedback from FDA on its Pivotal Trial Design for Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1

The two-arm Phase 2a study is expected to enroll 20 first-recurrent GBM patients to receive VBI’s cancer vaccine candidate, VBI-1901, in combination with either GM-CSF or AS01 B

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced biomarker data for EDP1815, its lead inflammation product candidate. Interim data from individuals in the ongoing Phase 1b clinical trial showed marked activity on multiple individual systemic markers of inflammation, including interleukin-6 (IL-6) and interleukin-8 (IL-8).

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for its experimental gene therapy program, PR006,

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2019.

Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2019.

China Pharmaceutical Holdings Limited (NYSE American: CPHI) (“China Pharma” or “Company”), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China , today announced that its subsidiary, Hainan Helpson Pharmaceutical & Biotechnology Co., Ltd. (“Helpson”) launched a new product.